Transfusion and Apheresis Science
Volume 42, Issue 3 , Pages 223-233, June 2010

An approach to prevent the severe adverse events associated with transfusion of FDA-approved blood products

NBRL, Inc., 195 Bournehurst Drive, Plymouth, MA 02360, United States

Received 5 June 2009; accepted 10 August 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S1473-0502(10)00064-9

doi:10.1016/j.transci.2009.08.001

Transfusion and Apheresis Science
Volume 42, Issue 3 , Pages 223-233, June 2010

Article Tools